FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular lymphoma July 6, 2022July 6, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: FDA approves Roche’s Lunsumio, a first-in-class…European Commission approves Roche’s first-in-class…FDA grants priority review to Roche’s bispecific…CHMP recommends EU conditional approval of Roche’s…New data for Roche’s Columvi and Lunsumio presented…U.S. FDA grants priority review to Roche’s…
